Biomarker Validation

Molecular Epidemiology of Chronic Diseases

Volumn , Issue , 2008, Pages 71-81

  Vineis, Paolo ^a   Garte, Seymour ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Biomarker behaviour and sampling variation; Biomarker blood collection; Biomarker validation; DNA protein crosslink measurement; Marker measurement errors; Measurement of variation; Polycyclic aromatic hydrocarbon (PAH); Receiver operating curve (ROC)

Indexed keywords

EID: 84890618967     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470725726.ch6     Document Type: Chapter

References (30)

1. Allison DB, Cui X, Page GP. 2006. Sabripour M. Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet 7: 55-65.
2. Baggerly KA, Morris JS, Edmonson SR et al. 2005. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 97: 307-309.
3. Beach AC, Gupta RC. 1992. Human biomonitoring and the 32P-postlabeling assay. Carcinogenesis 13: 1053-1074.
4. Bingham SA, Day NE, Luben R et al. 2003. European Prospective Investigation into Cancer and Nutrition. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet 3: 1496-1501.
5. Brennan P, Silman A. 1992. Statistical methods for assessing observer variability in clinical measures. Br Med J 304: 1491-1494.
6. Carmines EG, Zeller RA. 1979. Reliability and Validity Assessment. Sage: London.
7. D'Haeseleer P. How does gene expression clustering work? 2005. Nat Biotechnol 23: 1499-1501.
8. Diamandis EP. 2004. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 96: 353-356.
9. Esrig D, Spruck CH III, Nichols PW. 1993. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade and stage in bladder cancer. Am J Pathol 143: 1389-1397.
10. Fletcher RH, Fletcher SW, Wagner EH. 1988. Clinical Epidemiology-The Essentials, 2nd edn. Williams and Wilkins: Baltimore, MD.
11. Gormally E, Hainaut P, Caboux E et al. 2004. Amount of DNA in plasma and cancer risk: a prospective study. Int J Cancer 111: 746-649.
12. Gunter EW, Bowman BA, Caudill SP et al. 1996. Results of an international round robin for serum and wholeblood folate. Clin Chem 42: 1689-1694.
13. Hill AB. The environment and disease: association or causation? 1965. Proc R Soc Med 58: 295-300.
14. Holland NT, Smith MT, Eskenazi B et al. 2003. Biological sample collection and processing for molecular epidemilogal studies. Mutat Res 543: 217-234.
15. Komaromy-Hiller G, Nuttall KL, Ashwood ER. 1997. Effect of storage on serum vitamin B12 and folate stability. Ann Clin Lab Sci 27: 249-253.
16. Muti P, Trevisan M, Micheli A et al. 1996. Reliability of serum hormones in premenopausal and postmenopausal women over a one-year period. Cancer Epidemiol Biomarkers Prevent 5: 917-922.
17. Pfeiffer CM, Huff DL, Smith SJ et al. 1999. Comparison of plasma total homocysteine measurements in 14 laboratories: an international study. Clin Chem 45: 1261-1268.
18. Phillips DH, Castegnaro M, Autrup H et al. 1999. Standardization and validation of DNA adduct postlabelling methods: report of interlaboratory trials and production of recommended protocols. Mutagenesis 14: 301-315.
19. Pickard NA. 1989. Collection and handling of patients specimens. In Clinical Chemistry: Theory, Analysis and Correlation, 2nd edn, Kaplan LA, Pesce AJ (eds). C. V. Moody: St. Louis, MO.
20. Ransohoff DF. 2005a. Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst 16: 315-319.
21. Ransohoff DF. 2005b. Bias as a threat to the validity of cancer molecular-marker researc. Nat Rev Cancer 2005; 5: 142-149.
22. Riboli E, Haley NJ, De Waard F et al. 1995. Validity of urinary biomarkers of exposure to tobacco smoke following prolonged storage. Int J Epidemiol 24: 354-358.
23. Rundle AG, Vineis P, Ahsan H. 2005. Design options for molecular epidemiology research within cohort studies. Cancer Epidemiol Biomarkers Prevent 14: 1899-1907.
24. Steinberg K, Beck J, Nickerson D et al. 2002. DNA banking for epidemiologic studies: a review of current practices. Epidemiology 13: 246-254.
25. Taioli E, Kinney P, Zhitkovich A et al. 1994. Application of reliability models to studies of biomarker validation. Environ. Health Perspect 102: 306-309.
26. Thavasu PW, Longhurst S, Joel SP et al. 1992. Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditions. J Immunol Methods 153: 115-124.
27. Vineis P, Alavanja M, Garte S. 2004. Dose-response relationship in tobacco-related cancers of bladder and lung: a biochemical interpretation. Int J Cancer 1: 2-7.
28. Young DS, Bermes EW. 1986. Specimen collection and processing: sources of biological variation. In Textbook of Clinical Chemistry, Tiertz NW (ed.). W. B. Saunders: Philadelphia, PA.
29. Yanagisawa K, Shyr Y, Xu BJ et al. 2003. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 362: 433-439.
30. Ward CL, Dempsey MH, Ring CJ et al. 2004. Design and performance testing of quantitative real time PCR assays for influenza A and B viral load measurement. J Clin Virol 29: 179-188.